Business and FinanceBusiness and Finance
Thu, March 13, 2025
[ Today @ 07:21 AM ] - Kiplinger
Is 2025 a Bad Year To Retire?
[ Today @ 04:24 AM ] - Insider
The age of streaming inequality

Mallinckrodt and Endo plan merger as they look to recover from opioid litigation


Published on 2025-03-13 08:21:15 - MarketWatch
  Print publication without navigation

  • The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.

Mallinckrodt and Endo International, two pharmaceutical companies heavily impacted by litigation related to the opioid crisis, are reportedly in discussions to merge. This potential merger comes as both companies seek to stabilize their financial standings following significant legal settlements. Mallinckrodt, which recently emerged from bankruptcy, has been dealing with the aftermath of a $1.7 billion settlement for its role in the opioid epidemic, while Endo has also faced substantial legal challenges, including a $50 million settlement with Nevada. The merger talks aim at combining resources to better manage their ongoing legal and financial issues, potentially offering a path to recovery and operational continuity amidst the backdrop of the broader pharmaceutical industry's efforts to address the opioid crisis.

Read the Full MarketWatch Article at:
[ https://www.msn.com/en-us/money/general/mallinckrodt-and-endo-plan-merger-as-they-look-to-recover-from-opioid-litigation/ar-AA1AQiaW ]